Amendments to the Claims

1 to 34. (Canceled).

35. (Currently amended) A method of inducing a T_H1 polarized immune response ~~to an antigen,~~ comprising parenterally administering to a subject microparticles comprising at least one antigen entrapped or encapsulated in a biodegradable polymer, wherein said microparticles are sized such that the average diameter of said ~~the~~ microparticles is from about 2.2 μm to about 4.3 μm.

36. (Previously presented) The method of Claim 35, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μm.

37. (Previously presented) The method of Claim 35, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

38. (Previously presented) The method of Claim 35, wherein the microparticles are formed using a solvent evaporation method.

39. (Currently amended) The method of Claim 35, wherein the at least one antigen comprises a *B. pertussis* antigen.

40. (Previously presented) The method of Claim 35, wherein the parenteral administration is selected from the group consisting of intraperitoneal administration, subcutaneous administration and intramuscular administration.

41. (Currently amended) A vaccine formulation for enhancing a ~~the~~ T_H1 immune response ~~to at least one antigen~~ and adapted for parenteral administration comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of microparticles comprising at least one antigen entrapped or encapsulated in a biodegradable polymer, wherein said microparticles are sized such that the average diameter of said ~~the~~ microparticles is from about 2.2 μm to about 4.3 μm.

42. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 m.

43. (Previously presented) The vaccine formulation of Claim 41, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

44. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles are formed using a solvent evaporation method.

45. (Currently amended) The vaccine formulation of Claim 41, wherein the at least one antigen comprises a *B. pertussis* antigen.

46. (Currently amended) The vaccine formulation of Claim 41, wherein said formulation comprises ~~the microparticles comprise~~ at least 2 subpopulations of microparticles, each subpopulation comprising a different antigen entrapped or encapsulated by a biodegradable polymer, wherein said microparticles are sized such that the average diameter of said ~~the~~ microparticles is from about 2.2 μm to about 4.3 μm.

47. (New) A vaccine formulation for enhancing a T_H1 immune response and adapted for parenteral administration comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of microparticles comprising at least 2 subpopulations of microparticles, each subpopulation comprising a different antigen, each antigen entrapped or encapsulated by a biodegradable polymer, wherein said microparticles are sized such that the average diameter of said microparticles is from about 2.2 μm to about 4.3 μm.